Ergomed logo

ERGO - Ergomed News Story

685p -5.0  -0.7%

Last Trade - 9:22am

Small Cap
Market Cap £334.0m
Enterprise Value £325.2m
Revenue £68.3m
Position in Universe 625th / 1807

Ergomed plc - Exercise of options

Thu 21st June, 2018 9:11am
RNS Number : 1153S
Ergomed plc
21 June 2018





Exercise of options


London, UK - 21 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that it has issued 47,000 new ordinary shares of 1p each in the Company ('New Ordinary Shares'). The New Ordinary Shares have been allotted pursuant to exercise of share options awarded to two individuals under the Ergomed plc Long Term Incentive Plan.


Application has been made to the London Stock Exchange for 47,000 Ordinary Shares to be admitted to trading on AIM ('Admission').  It is expected that Admission will occur at 8:00 a.m. on 22 June 2018. The Ordinary Shares will rank pari passu with the existing ordinary shares in the Company.


Following Admission, the Company's enlarged issued share capital and total number of voting rights will be 44,858,602 Ordinary Shares.






Ergomed plc

   Tel: +44 (0) 1483 503 205

Stephen Stamp (Chief Executive Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

N+1 Singer

Tel: +44 (0) 20 7496 3000

Aubrey Powel (Joint Broker)

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke



About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit:



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.